Author

M. Effenberger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

D. H. Busch· 4 shared K. Schober· 3 shared C. Stemberger· 2 shared C. Tschulik· 2 shared L. Germeroth· 2 shared M. P. Poltorak· 2 shared S. P. Fraessle· 2 shared V. Cletiu· 2 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

D. H. Busch

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Miniaturized CAR knocked onto CD3epsilon extends TCR function with CAR specificity under control of endogenous TCR signaling cascade

K. Manske, L. Dressler, S. P. Fraessle, M. Effenberger, C. Tschulik, V. Cletiu, E. Benke, M. Wagner, K. Schober, T. R. Mueller, D. H. Busch, C. Stemberger, L. Germeroth, M. P. Poltorak

This paper describes a method to miniaturize CAR T cells by integrating only the antigen-binding domain under the control of the endogenous TCR signaling cascade, preserving TCR function while enabling CAR specificity.

bioRxiv · May 30, 2023Bioengineering

Activation-inducible CAR expression enables precise control over engineered CAR T cell function

S. P. Fraessle, C. Tschulik, M. Effenberger, V. Cletiu, M. Gerget, K. Schober, D. H. Busch, L. Germeroth, C. Stemberger, M. P. Poltorak

This paper presents activation-inducible CAR T cells using CRISPR-mediated integration, enabling controlled CAR expression based on T cell activation status.

bioRxiv · Nov 8, 2022 · PreprintImmunology

Interleukin-11 plays a key role in human and mouse alcohol-related liver disease

M. Effenberger, F. Grabherr, B. Schaefer, C. Grander, L. Mayr, J. Schwaerzler, B. Enrich, P. Moser, J. Fink, A. Pedrini, N. Jaschke, M. Freund, A. Loizides, R. Bale, D. Putzer, , H. Tilg

This study shows IL-11 is elevated in severe liver disease and blocking it reduces inflammation in alcohol-related liver disease in humans and mice.

bioRxiv · Aug 24, 2021 · PreprintImmunology

Spatial and temporal plasticity of neoantigen-specific T-cell responses bases on characteristics associated to antigen and TCR

E. Braeunlein, G. Lupoli, E. T. Abalrous, N. de Andrade Kraetzig, D. Gosmann, F. Fuechsl, L. Wietbrock, S. Lange, T. Engleitner, H. Lan, S. Audehm, M. Effenberger, M. Boxberg, K. Steiger, Y. Chang, , A. M. Krackhardt

The paper characterizes neoantigen-specific T-cell receptors in a melanoma patient, showing that low-avidity TCRs can provide effective anti-tumor responses and persist long-term in blood and tissues.

bioRxiv · Feb 2, 2021 · PreprintImmunology

Systematic identification of cancer-specific MHC-binding peptides with RAVEN

M. C. Baldauf, J. S. Gerke, A. Kirschner, F. Blaeschke, M. Effenberger, K. Schober, R. Alba Rubio, T. Kanaseki, M. M. Kiran, M. Dallmayer, J. Musa, N. Akpolat, A. N. Akatli, F. C. Rosman, O. Ozen, , T. G. Grunewald

The paper introduces RAVEN, a software tool that identifies cancer-specific genes encoding MHC-affine peptides from gene expression data, validated across 50 cancer types.

bioRxiv · Sep 24, 2017Immunology